Improving consistency for a Mefenamic acid immediate release formulation

Prasad, Elke and Robertson, John and Halbert, Gavin (2020) Improving consistency for a Mefenamic acid immediate release formulation. Journal of Pharmaceutical Sciences. ISSN 0022-3549

[thumbnail of Prasad-etal-JPS-2020-Improving-consistency-for-a-mefenamic-acid-immediate]
Preview
Text (Prasad-etal-JPS-2020-Improving-consistency-for-a-mefenamic-acid-immediate)
Prasad_etal_JPS_2020_Improving_consistency_for_a_mefenamic_acid_immediate.pdf
Accepted Author Manuscript
License: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 logo

Download (2MB)| Preview

    Abstract

    The objective of this study was to develop an immediate release dose form containing 250 mg Mefenamic acid (MFA) presented as a crystalline solid dispersion in order to achieve improved consistency in drug release through a simplified formulation compared to a commercial product. An MFA-Soluplus®-Sorbitol polymer matrix was developed using an HME process based on rheological screening assays of physical mixtures. The physico-chemical properties of these formulations were assessed by thermal analysis, FTIR, mechanical testing and SEM image analysis, confirming the crystalline character and stable polymorphic form I of the API in the polymer matrix. A faster release and a significant improvement in consistency (± 6 %) of drug release was observed compared to a commercially available MFA product (± 17 %) (250 mg capsule). This study illustrates advantages of applying a structured development program aimed at retaining API physical properties in the final dosage form.

    ORCID iDs

    Prasad, Elke ORCID logoORCID: https://orcid.org/0000-0002-5412-9374, Robertson, John ORCID logoORCID: https://orcid.org/0000-0002-2191-1319 and Halbert, Gavin;